NYSEARCA:TRXC - NYSE Arca -
4.08
-0.46 (-10.13%)
The current stock price of TRXC is 4.08 null. In the past month the price increased by 21.79%. In the past year, price increased by 837.93%.
TransEnterix Inc. designs, develops and manufactures medical-devices. It offers SPIDER(R) Surgical System, a laparoscopic surgical platform that allows intra-abdominal triangulation procedures to be performed with articulating instruments through a single site. The company is primarily focused on the development and commercialization of SurgiBot, a patient-side minimally invasive surgical robotic system. TransEnterix Inc., formerly known as SafeStitch Medical, Inc., is based in United States.
Transenterix Inc
635 DAVIS DRIVE SUITE 300
MORRISVILLE NC 27560
CEO: Anthony Fernando
Phone: 919-765-8400
The current stock price of TRXC is 4.08 null. The price decreased by -10.13% in the last trading session.
The exchange symbol of Transenterix Inc is TRXC and it is listed on the NYSE Arca exchange.
TRXC stock is listed on the NYSE Arca exchange.
Transenterix Inc (TRXC) has a market capitalization of 582.53M null. This makes TRXC a Small Cap stock.
Transenterix Inc (TRXC) has a support level at 3.71 and a resistance level at 4.55. Check the full technical report for a detailed analysis of TRXC support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TRXC does not pay a dividend.
Transenterix Inc (TRXC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.57).
ChartMill assigns a technical rating of 7 / 10 to TRXC. When comparing the yearly performance of all stocks, TRXC is one of the better performing stocks in the market, outperforming 99.13% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to TRXC. TRXC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months TRXC reported a non-GAAP Earnings per Share(EPS) of -1.5699999999999998. The EPS increased by 37.2% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -2150% | ||
ROA | -73.93% | ||
ROE | N/A | ||
Debt/Equity | 0.04 |
ChartMill assigns a Buy % Consensus number of 60% to TRXC. The Buy consensus is the average rating of analysts ratings from 2 analysts.